Cannabis Is a Budding Strategy Against Ovarian Cancer

A combination of two cannabis-derived compounds can target ovarian cancer cells while sparing healthy cells, offering early clues toward new treatment possibilities.

Written byLaura Tran, PhD
| 2 min read
Image of marijuana buds surrounding a small jar of cannabis oil.
Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

When it comes to treating ovarian cancer, existing drugs are often limited in effectiveness and can cause significant side effects, underscoring the need for new options. In response, researchers are exploring alternative drugs, including herbal-based strategies.

For instance, a research group from Khon Kaen University investigated the cannabis plant, which has been used to help relieve side effects of cancer treatments. Namely, they focused on the individual and combined effects of two cannabis compounds on human ovarian cancer cell lines: cannabidiol (CBD), which is non-psychoactive, and delta-9-tetrahydrocannabinol (THC), which is responsible for cannabis’s psychoactive effects and “high” feeling.

In a recent study, published in Frontiers in Pharmacology, the same research group demonstrated that a combination of CBD and THC successfully killed a large proportion of ovarian cancer cells while sparing healthy cells in vitro.1 Their findings lay a foundation for alternative treatments.

First, the researchers assessed two ovarian cancer cell lines: one that is sensitive to platinum-derived drugs and another that is resistant. Platinum drugs are often used as initial ovarian cancer treatments. They treated these groups and healthy cells with different doses of CBD, THC, and ratios of CBD:THC.

Of these treatments, the CBD:THC combination at a one-to-one ratio had a synergistic effect, producing the best results: It led to in fewer and smaller cancer cell colonies, induced cell death, and decreased the cells’ ability to migrate. The researchers also noted that the treatment exhibited selective toxicity towards cancer cells, leaving healthy cells unharmed.

To better understand the mechanisms behind these anti-cancer effects, the researchers examined key cell signaling pathways. In ovarian cancer cells, the PI3K/AKT/mTOR signaling pathway is often hyperactivated, regulated by phosphorylation, and contributes to tumor development. When the team tested the CBD:THC combination on ovarian cancer cell lines, they observed reduced phosphorylation of proteins within the PI3K/AKT/mTOR pathway. They also detected an increase, or restoration, of a tumor-suppressor protein, which may further contribute to the dampened signaling activity.

“Although our study is still preliminary, it lays an important foundation for future research into the potential applications of CBD and THC in ovarian cancer treatment,” said study coauthor Siyao Tong in a press release.

Related Topics

Meet the Author

  • Laura Tran, PhD

    Laura Tran is an Assistant Editor at The Scientist. She has a background in microbiology. Laura earned her PhD in integrated biomedical sciences from Rush University, studying how circadian rhythms and alcohol impact the gut. While completing her studies, she wrote for the Chicago Council on Science and Technology and participated in ComSciCon Chicago in 2022. In 2023, Laura became a science communication fellow with OMSI, continuing her passion for accessible science storytelling.

    View Full Profile
Share
You might also be interested in...
Loading Next Article...
You might also be interested in...
Loading Next Article...
Illustration of a developing fetus surrounded by a clear fluid with a subtle yellow tinge, representing amniotic fluid.
January 2026

What Is the Amniotic Fluid Composed of?

The liquid world of fetal development provides a rich source of nutrition and protection tailored to meet the needs of the growing fetus.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies

Parse Logo

Parse Biosciences and Graph Therapeutics Partner to Build Large Functional Immune Perturbation Atlas

Sino Biological Logo

Sino Biological's Launch of SwiftFluo® TR-FRET Kits Pioneers a New Era in High-Throughout Kinase Inhibitor Screening

SPT Labtech Logo

SPT Labtech enables automated Twist Bioscience NGS library preparation workflows on SPT's firefly platform